Небулайзеры для длительной поддерживающей терапии обструктивных заболеваний легких
Небулайзеры для длительной поддерживающей терапии обструктивных заболеваний легких
Авдеев С.Н. Небулайзеры для длительной поддерживающей терапии обструктивных заболеваний легких. Consilium Medicum. 2008; 10 (10): 34–41.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Tashkin DP. The Role of Nebulizers in Airways Disease Management. Touch Briefings 2007; 27–31.
2. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
3. Huchon G. Metered dose inhalers part and present: advantages and limitations. Eur Respir Rev 1997; 7 (41): 26–8.
4. Borgstrom L, Bisgaard H, O'Callaghan C, Pedersen S. Dry-powder inhalers. Ed: Bisgaard H, O'Callaghan C, Smaldone G. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2002; 421–48.
5. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304.
6. Lavorini F, Magnan A, Dubus JC et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102: 593–604.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–61.
8. Boe J, Dennis JH, O'Driscoll BR et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
9. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47: 1406–18.
10. Vecellio L. The mesh nebulizer: a recent technical innovation for aerosol delivery. Breathe 2006; 2: 253–60.
11. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver 2005; 2: 377–90.
12. Newman S, Gee-Turner A. The Omron MicroAir vibrating mesh technology nebuliser, a 21st century approach to inhalation therapy. J Appl Ther Res 2005; 5: 429–33.
13. Чучалин А.Г., Княжеская Н.П., Потапова М.О. «Место небулайзеров в ингаляционной терапии хронических обструктивных заболеваний лёгких». Рус. мед. журн. 2006; 14(7).
14. Dennis J, Pieron C, Gee-Turner A et al. Omron VVT Nebulizer Performance. J Aerosol Med 2007; 20: 365–92.
15. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 2005; 127: 335–71.
16. British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax 1997; 52 (Suppl. 2): S1–S24.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2006, National Institutes of Health/WHO. Available from http://www.goldcopd.com.
18. ERS Task Force. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
19. O'Driscoll BR, Kay EA, Taylor RJ et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317–25.
20. Goldman JM, Teale C, Muiers MF. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. Respir Med 1992; 86: 33–8.
21. Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. Eur Respir J 1992; 5: 424–9.
22. Barta S, Crawford A, Roberts C. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002; 96: 375–81.
23. Marcus P, Oppenheimer EA, Patel PA et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96: 736–43.
24. Tashkin D, Klein G, Colman SS et al. Comparing COPD treatment: nebulizer, metered dose inhaler and concomitant therapy. Am J Med 2007; 120: 435–41.
2. Cochrane MG, Bala MV, Downs KE et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–50.
3. Huchon G. Metered dose inhalers part and present: advantages and limitations. Eur Respir Rev 1997; 7 (41): 26–8.
4. Borgstrom L, Bisgaard H, O'Callaghan C, Pedersen S. Dry-powder inhalers. Ed: Bisgaard H, O'Callaghan C, Smaldone G. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2002; 421–48.
5. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96: 293–304.
6. Lavorini F, Magnan A, Dubus JC et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008; 102: 593–604.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–61.
8. Boe J, Dennis JH, O'Driscoll BR et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
9. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47: 1406–18.
10. Vecellio L. The mesh nebulizer: a recent technical innovation for aerosol delivery. Breathe 2006; 2: 253–60.
11. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver 2005; 2: 377–90.
12. Newman S, Gee-Turner A. The Omron MicroAir vibrating mesh technology nebuliser, a 21st century approach to inhalation therapy. J Appl Ther Res 2005; 5: 429–33.
13. Чучалин А.Г., Княжеская Н.П., Потапова М.О. «Место небулайзеров в ингаляционной терапии хронических обструктивных заболеваний лёгких». Рус. мед. журн. 2006; 14(7).
14. Dennis J, Pieron C, Gee-Turner A et al. Omron VVT Nebulizer Performance. J Aerosol Med 2007; 20: 365–92.
15. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. Chest 2005; 127: 335–71.
16. British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax 1997; 52 (Suppl. 2): S1–S24.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2006, National Institutes of Health/WHO. Available from http://www.goldcopd.com.
18. ERS Task Force. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–42.
19. O'Driscoll BR, Kay EA, Taylor RJ et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317–25.
20. Goldman JM, Teale C, Muiers MF. Simplifying the assessment of patients with chronic airflow limitation for home nebulizer therapy. Respir Med 1992; 86: 33–8.
21. Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulized bronchodilators in severe airflow limitation. Eur Respir J 1992; 5: 424–9.
22. Barta S, Crawford A, Roberts C. Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002; 96: 375–81.
23. Marcus P, Oppenheimer EA, Patel PA et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96: 736–43.
24. Tashkin D, Klein G, Colman SS et al. Comparing COPD treatment: nebulizer, metered dose inhaler and concomitant therapy. Am J Med 2007; 120: 435–41.
Авторы
С.Н.Авдеев
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.